Australia's most trusted
source of pharma news
Thursday, 25 April 2024
Posted 7 December 2021 PM
Celltrion Healthcare's Regkirona has become the fifth Covid therapeutic provisionally approved by the TGA with the company now preparing to deploy an MSL team if a supply agreement is reached with the Department of Health.
Regkirona, which is administered intravenously, was yesterday (Monday) registered in Australia for the treatment of adults with COVID-19 who do not require supplemental oxygen and are at increased risk of progressing to severe disease.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.